Jupiter Neurosciences Inc (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company developing resveratrol-based therapeutics for neurological and other diseases. The company's lead product candidate is JOTROL, a proprietary formulation of resveratrol designed to address the bioavailability and gastrointestinal tolerability limitations that have historically prevented resveratrol from advancing through pharmaceutical approval pathways. JUNS has not yet generated product revenue from JOTROL, as the compound remains in clinical development as of the fiscal year ended December 31, 2025. The company also markets Nugevia, a dietary supplement line subject to FDA post-market surveillance under DSHEA. JUNS relies on Catalent Pharmaceutical Services, Inc. as its sole contract manufacturer for JOTROL clinical trial supplies, with no backup manufacturer in place. The company has entered into service agreements with partners in Southeast Asia covering chemistry, manufacturing and controls, regulatory affairs, and clinical trial management, and is in active negotiations with Dominant Treasure Health Company Limited for further Asian market development.

Revenue model

Jupiter Neurosciences has not disclosed commercial product revenue from JOTROL as of FY2025. The company issued shares to Asian partners as pre-payment for services and carries deferred revenue on its balance sheet as of December 31, 2025. Revenue generation is contingent on regulatory approval of product candidates.

Products and services

JOTROL: proprietary resveratrol pharmaceutical formulation in clinical development for neurological indications including Parkinson's disease. Nugevia: dietary supplement product line containing resveratrol and other ingredients such as astaxanthin, subject to FDA DSHEA post-market surveillance.

Customers and end markets

Target end markets include patients with neurological disorders, specifically Parkinson's disease. No commercial customer base for JOTROL has been established as of the fiscal year ended December 31, 2025.

Value-chain role

Clinical-stage drug developer. Outsources manufacturing of JOTROL clinical trial supplies entirely to Catalent Pharmaceutical Services, Inc. as sole-source contract manufacturer. Engages contract research organizations and contract development and manufacturing organizations for clinical and regulatory activities.

Geographic exposure

United States-based operations with active business development in Southeast Asia through service agreements and negotiations with Dominant Treasure Health Company Limited, a BVI-incorporated entity.

Competitors

Large pharmaceutical companies developing Parkinson's disease treatments, Small biotechnology companies targeting the same neurological indications

Source: SEC 10-K, filed 2026-04-01

Industry: Pharmaceutical Preparations